ShareValue.ai

ShareValue scores for EYE.AU: Valuation 55, Quality 54, Growth 55, Health 35.

Nova EYE Medical Ltd logo

EYE.AU
ASX

Nova EYE Medical Ltd

A$0.10(-4.76%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

4% to 17%
Valuation
55
Fair Value
Price vs Value
Quality
54
Moderate
Business Strength
Growth
55
Moderate
Revenue & Earnings
Health
35
Stressed
Financial Stability
Momentum
47
Neutral
Price Trend

Company Details

About

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It also engaged in the commercialisation of the subthreshold nano-pulse ophthalmic laser; 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma; iTrack Advance; and Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.

Score Analysis

AI Investment Thesis

Data as of:Jun 29, 2026
|
Last calculated:Jun 29, 2026